Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Hallén

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Cardiology|April 21, 2012
Troponin for the estimation of infarct size: what have we learned?Jonas Hallén
Biomarkers in Medicine|December 8, 2010
A window into your heart: taking cardiac troponin to the next levelJonas Hallén, Dan Atar
European Heart Journal. Cardiovascular Pharmacotherapy|July 31, 2018
Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerationsJonas Hallén, Nadarajah Sreeharan
The American Journal of Cardiology|May 2, 2009
In ST-Elevation myocardial infarction patients receiving primary percutaneous coronary intervention, admission cardiac troponin T and peak cardiac troponin T values differ in their prognostic propertiesJonas Hallén, Dan Atar
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2024
ReplyJörg H W Distler, Jonas Hallén
American Journal of Therapeutics|September 23, 2009
Effects of FX06 in vitro on platelet, coagulation, and fibrinolytic biomarkers in volunteers and patients with documented coronary artery diseaseJonas Hallén, Dan Atar, Victor Serebruany
The American Journal of Cardiology|May 25, 2010
Optimal time-point of ST-segment assessment for risk-stratification following primary percutaneous coronary interventionJonas Hallén, Dan Atar, Maria Sejersten, et al.
Heart (British Cardiac Society)|July 6, 2011
Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarctionLennart Nilsson, Jonas Hallén, Dan Atar, et al.
The American Journal of Cardiology|April 21, 2010
Influence of ST-segment recovery on infarct size and ejection fraction in patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary interventionJonas Hallén, Maria Sejersten, Per Johanson, et al.
Clinical Laboratory|November 21, 2012
Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experienceTrygve Sørdahl Hall, Jonas Hallén, Stefan Agewall, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Cardiology|April 21, 2012
Troponin for the estimation of infarct size: what have we learned?Jonas Hallén
Biomarkers in Medicine|December 8, 2010
A window into your heart: taking cardiac troponin to the next levelJonas Hallén, Dan Atar
European Heart Journal. Cardiovascular Pharmacotherapy|July 31, 2018
Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerationsJonas Hallén, Nadarajah Sreeharan
The American Journal of Cardiology|May 2, 2009
In ST-Elevation myocardial infarction patients receiving primary percutaneous coronary intervention, admission cardiac troponin T and peak cardiac troponin T values differ in their prognostic propertiesJonas Hallén, Dan Atar
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2024
ReplyJörg H W Distler, Jonas Hallén
American Journal of Therapeutics|September 23, 2009
Effects of FX06 in vitro on platelet, coagulation, and fibrinolytic biomarkers in volunteers and patients with documented coronary artery diseaseJonas Hallén, Dan Atar, Victor Serebruany
The American Journal of Cardiology|May 25, 2010
Optimal time-point of ST-segment assessment for risk-stratification following primary percutaneous coronary interventionJonas Hallén, Dan Atar, Maria Sejersten, et al.
Heart (British Cardiac Society)|July 6, 2011
Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarctionLennart Nilsson, Jonas Hallén, Dan Atar, et al.
The American Journal of Cardiology|April 21, 2010
Influence of ST-segment recovery on infarct size and ejection fraction in patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary interventionJonas Hallén, Maria Sejersten, Per Johanson, et al.
Clinical Laboratory|November 21, 2012
Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experienceTrygve Sørdahl Hall, Jonas Hallén, Stefan Agewall, et al.
Pageof 4